These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 15202936)

  • 21. Modulation of P-glycoprotein function and reversal of multidrug resistance by (-)-epigallocatechin gallate in human cancer cells.
    Qian F; Wei D; Zhang Q; Yang S
    Biomed Pharmacother; 2005 Apr; 59(3):64-9. PubMed ID: 15795098
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers.
    Bajo AM; Schally AV; Halmos G; Nagy A
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3742-8. PubMed ID: 14506166
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: Involvement of cytotoxic effect on vascular endothelial cells.
    Ogawara K; Un K; Tanaka K; Higaki K; Kimura T
    J Control Release; 2009 Jan; 133(1):4-10. PubMed ID: 18840484
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of multidrug resistance, antisense RNA on the chemosensitivity of hepatocellular carcinoma cells.
    Li B; Ye T; Zhao L; Li DH; Gou XH; Zhao LY; Han L; Chen L; Yan LN; Gong JP
    Hepatobiliary Pancreat Dis Int; 2006 Nov; 5(4):552-9. PubMed ID: 17085341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-dose acetaminophen inhibits the lethal effect of doxorubicin in HepG2 cells: the role of P-glycoprotein and mitogen-activated protein kinase p44/42 pathway.
    Manov I; Bashenko Y; Eliaz-Wolkowicz A; Mizrahi M; Liran O; Iancu TC
    J Pharmacol Exp Ther; 2007 Sep; 322(3):1013-22. PubMed ID: 17526808
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
    Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The synergistic reversal effect of multidrug resistance by quercetin and hyperthermia in doxorubicin-resistant human myelogenous leukemia cells.
    Shen J; Zhang W; Wu J; Zhu Y
    Int J Hyperthermia; 2008 Mar; 24(2):151-9. PubMed ID: 18283591
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Establishment of hepatocellular carcinoma multidrug resistant monoclone cell line HepG2/mdr1.
    Chen YB; Yan ML; Gong JP; Xia RP; Liu LX; Li N; Lu SC; Zhang JG; Zeng DB; Xie JG; Yang JY; Yan LN
    Chin Med J (Engl); 2007 Apr; 120(8):703-7. PubMed ID: 17517188
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Voacamine, an alkaloid extracted from Peschiera fuchsiaefolia, inhibits P-glycoprotein action in multidrug-resistant tumor cells.
    Meschini S; Marra M; Condello M; Calcabrini A; Federici E; Dupuis ML; Cianfriglia M; Arancia G
    Int J Oncol; 2005 Dec; 27(6):1597-603. PubMed ID: 16273216
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted therapy of human laryngeal squamous cell carcinoma in vitro by antisense oligonucleotides directed against telomerase reverse transcriptase mRNA.
    Tao Z; Chen S; Wu Z; Xiao B; Liu J; Hou W
    J Laryngol Otol; 2005 Feb; 119(2):92-6. PubMed ID: 15829059
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overcoming multidrug resistance in human tumor cells using free and liposomally encapsulated antisense oligodeoxynucleotides.
    Thierry AR; Rahman A; Dritschilo A
    Biochem Biophys Res Commun; 1993 Feb; 190(3):952-60. PubMed ID: 8094959
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CJY, an isoflavone, reverses P-glycoprotein-mediated multidrug-resistance in doxorubicin-resistant human myelogenous leukaemia (K562/DOX) cells.
    Ji BS; He L
    J Pharm Pharmacol; 2007 Jul; 59(7):1011-5. PubMed ID: 17637197
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tamoxifen circumvents the multidrug resistance in fresh human gastrointestinal cancer cells.
    Hotta T; Tanimura H; Yamaue H; Iwahashi M; Tani M; Tsunoda T; Tamai M; Noguchi K; Mizobata S; Arii K; Terasawa H
    J Surg Res; 1996 Nov; 66(1):31-5. PubMed ID: 8954828
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Self-assembled oligopeptide nanostructures for co-delivery of drug and gene with synergistic therapeutic effect.
    Wiradharma N; Tong YW; Yang YY
    Biomaterials; 2009 Jun; 30(17):3100-9. PubMed ID: 19342093
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selection of antisense oligonucleotides for reversal of multidrug resistance in breast carcinoma cells.
    Gao P; Zhou GY; Lei DP; Zhang XF; Li L; Xu JW; Lin XY
    Cytotherapy; 2007; 9(8):795-801. PubMed ID: 17917879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of telomerase with human telomerase reverse transcriptase antisense increases the sensitivity of tumor necrosis factor-alpha-induced apoptosis in prostate cancer cells.
    Gao XD; Chen YR
    Asian J Androl; 2007 Sep; 9(5):697-704. PubMed ID: 17712489
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantification intracellular levels of oligodeoxynucleotide-doxorubicin conjugate in human carcinoma cells in situ.
    Ren Y; Wei D
    J Pharm Biomed Anal; 2004 Oct; 36(2):387-91. PubMed ID: 15496334
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity.
    Veronese FM; Schiavon O; Pasut G; Mendichi R; Andersson L; Tsirk A; Ford J; Wu G; Kneller S; Davies J; Duncan R
    Bioconjug Chem; 2005; 16(4):775-84. PubMed ID: 16029018
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Involvement of doxorubicin-induced Fas expression in the antitumor effect of doxorubicin on Lewis lung carcinoma in vivo.
    Yoshimoto Y; Kawada M; Ikeda D; Ishizuka M
    Int Immunopharmacol; 2005 Feb; 5(2):281-8. PubMed ID: 15652759
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of multidrug-resistant murine leukemia with antisense mdr1 oligodeoxynucleotides.
    Hiratake S; Azuma E; Nishiguchi Y; Nagai M; Ido M; Komada Y; Sakurai M
    Biomed Pharmacother; 1997; 51(6-7):276-83. PubMed ID: 9309248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.